Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00263315 | Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis | PHASE2 | COMPLETED | 320 | — | — | Jan 1, 2000 | May 1, 2006 | Aug 18, 2006 | 2 | Netherlands |
| Name | Type | Description |
|---|---|---|
| nebulised liposomal amphotericin B | DRUG | - |
Inclusion Criteria: 1. Male or female hospitalized patients aged \> 18 yr 2. The patient has a hematologic malignancy or will receive a bone-marrow transplant 3. The patient starts with a course of chemotherapy within 4 days or is already neutropenic at admission 4. The expected duration of severe ...